Annovis Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Annovis Bio, Inc. (ANVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-14
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-06-30 was 0.00%.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-13 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 0.00% 10-K · filed 2025-03-21 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2024-05-10 | |||
| 2023-12-31 | 0.00% 10-K · filed 2024-03-29 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-07-29 | 0.00% 10-Q · filed 2020-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |